Advice

in the absence of a submission from the holder of the marketing authorisation:

pixantrone (Pixuvri®) is not recommended for use within NHS Scotland.

Indication under review: As monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non Hodgkin B-cell Lymphomas.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice49KB (PDF)

Download

Medicine details

Medicine name:
pixantrone (Pixuvri)
SMC ID:
1138/16
Indication:
As monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non Hodgkin B-cell Lymphomas.
Pharmaceutical company
CTI Life Sciences Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published
07 February 2016